A novel antimetabolite: TAS-102 for metastatic colorectal cancer

被引：8
|
作者：
Miyamoto, Yuji [1 ,2 ]
Lenz, Heinz-Josef [2 ]
Baba, Hideo [1 ]
机构：
[1] Kumamoto Univ, Dept Surg Gastroenterol, Grad Sch Med Sci, 1-1-1 Honjo, Kumamoto 8608556, Japan
[2] Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Div Med Oncol, Los Angeles, CA 90033 USA
来源：
EXPERT REVIEW OF CLINICAL PHARMACOLOGY | 2016年 / 9卷 / 03期
关键词：
refractory; salvage line; metastatic colorectal cancer; TAS-102; phase III; intolerant; chemotherapy; ORAL CHEMOTHERAPEUTIC-AGENT; RANDOMIZED PHASE-III; THYMIDINE KINASE 1; SOLID TUMORS; THYMIDYLATE SYNTHASE; FLUORINATED PYRIMIDINES; 1ST-LINE TREATMENT; ANTITUMOR-ACTIVITY; COMBINATION ANTIMETABOLITE; SYNERGISTIC INTERACTION;
D O I：
10.1586/17512433.2016.1133285
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
TAS-102 is a new oral anti-tumor drug, composed of a thymidine-based nucleoside analog (trifluridine: FTD) and a thymidine phosphorylase inhibitor (tipiracil hydrochloride: TPI). TAS-102 has been shown to significantly improve overall survival and progression-free survival in patients with refractory metastatic colorectal cancer (mCRC) in placebo-controlled randomized phase II and III trials. The current review summarizes mechanisms of action, pharmacokinetics/dynamics and preclinical and clinical data of TAS-102 in colorectal cancer. TAS-102 is a new salvage-line treatment option for patients with mCRC. TAS-102 is well tolerated and has great potential in future clinical drug combination therapies.
引用
收藏
页码：355 / 365
页数：11
相关论文
共 50 条
  • [1] TAS-102 in metastatic colorectal cancer
    Burki, Talha Khan
    [J]. LANCET ONCOLOGY, 2018, 19 (01): : E18 - E18
  • [2] TAS-102 for metastatic refractory colorectal cancer
    Cleghorn, Sean
    [J]. LANCET ONCOLOGY, 2015, 16 (07): : E314 - E314
  • [3] TAS-102 for the treatment of metastatic colorectal cancer
    Salvatore, Lisa
    Rossini, Daniele
    Moretto, Roberto
    Cremolini, Chiara
    Schirripa, Marta
    Antoniotti, Carlotta
    Marmorino, Federica
    Loupakis, Fotios
    Falcone, Alfredo
    Masi, Gianluca
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2015, 15 (11) : 1283 - 1292
  • [4] Treatment of TAS-102 in patients with metastatic colorectal cancer
    Ota, Takayo
    Tsukuda, Hiroshi
    Hasegawa, Yoshikazu
    Miyatake, Nozomi
    Suzumura, Tomohiro
    Fukuoka, Masahiro
    [J]. ANNALS OF ONCOLOGY, 2016, 27
  • [5] Retrospective analysis of TAS-102 for metastatic colorectal cancer
    Aoki, M.
    Shimamoto, F.
    Ikegami, T.
    Yamaguchi, T.
    Terazawa, T.
    Kii, T.
    Goto, M.
    Higuchi, K.
    [J]. ANNALS OF ONCOLOGY, 2017, 28
  • [6] TAS-102 plus bevacizumab in metastatic colorectal cancer
    Colloca, Giuseppe A.
    Venturino, Antonella
    [J]. LANCET ONCOLOGY, 2020, 21 (05): : E226 - E226
  • [7] TAS-102: more than an antimetabolite
    Peters, Godefridus J.
    Bijnsdorp, Irene V.
    [J]. LANCET ONCOLOGY, 2012, 13 (12): : E518 - E519
  • [8] Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer
    Mayer, Robert J.
    Van Cutsem, Eric
    Falcone, Alfredo
    Yoshino, Takayuki
    Garcia-Carbonero, Rocio
    Mizunuma, Nobuyuki
    Yamazaki, Kentaro
    Shimada, Yasuhiro
    Tabernero, Josep
    Komatsu, Yoshito
    Sobrero, Alberto
    Boucher, Eveline
    Peeters, Marc
    Tran, Ben
    Lenz, Heinz-Josef
    Zaniboni, Alberto
    Hochster, Howard
    Cleary, James M.
    Prenen, Hans
    Benedetti, Fabio
    Mizuguchi, Hirokazu
    Makris, Lukas
    Ito, Masanobu
    Ohtsu, Atsushi
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (20): : 1909 - 1919
  • [9] TAS-102 plus bevacizumab in metastatic colorectal cancer Reply
    Pfeiffer, Per
    Moller, Soren
    Winther, Stine Braendegaard
    Qvortrup, Camilla
    [J]. LANCET ONCOLOGY, 2020, 21 (05): : E227 - E227
  • [10] TAS-102: a novel antimetabolite for the 21st century
    Uboha, Nataliya
    Hochster, Howard S.
    [J]. FUTURE ONCOLOGY, 2016, 12 (02) : 153 - 163
12345